Skip to main content
. Author manuscript; available in PMC: 2016 May 31.
Published in final edited form as: Cell Rep. 2016 May 5;15(7):1394–1400. doi: 10.1016/j.celrep.2016.04.024

Figure 1. Metformin improves fasting and postprandial indices of insulin sensitivity.

Figure 1

(A) HOMA-IR and (B) insulin to glucagon ratio. (C) Whole-body insulin sensitivity (Si) (D) β-cell responsivity and (E) Disposition index modeled after a mixed-meal challenge. Basal and postprandial plasma values and area above baseline (AAB) after two weeks of metformin compared to placebo for (F) Glucose (G) C-peptide (H) Insulin and (I) Glucagon. Postprandial glucagon was decreased with metformin at 120, 180 and 240 minutes. *P<0.05, **P<0.01, ***P<0.001 metformin vs. placebo; Data presented as mean ± SEM.